FDA Clears New Cardiovascular CT Scanners
Offering dedicated computed tomography (CT) assessment of the cardiovascular system, the SpotLight and SpotLight Duo systems reportedly provide high-resolution imaging for diagnosis and monitoring of cardiovascular diseases.
The Food and Drug Administration (FDA) has granted 510(k) clearance for the SpotLight and SpotLight Duo computed tomography (CT) scanners that are specifically geared to cardiovascular assessments.
In addition to a 25 cm field of view for dedicated cardiovascular CT scans, key benefits of the SpotLight system include best-in-class specifications for one beat whole heart coverage (14 cm), spatial resolution (0.5 mm detector) and temporal resolution (120 msec), according to Arineta, the developer of the SpotLight and SpotLight Duo scanners.
“… The new SpotLight systems continue Arineta’s history of clinical innovation,” said Scott Schubert, the CEO of Arineta. “Our vision is to grow cardiac CT as the front-line non-invasive test for diagnosing, therapy planning and monitoring of cardiovascular disease, the number one cause of death and costs for healthcare worldwide.”
Arineta said the SpotLight Duo offers whole organ acquisition with 4D imaging for enhanced visualization of vascular flow and organ motion. The SpotLight Duo also features 45 cm high resolution scans to facilitate full cardiothoracic CT assessments for conditions such as lung cancer, COVID-19 and other pulmonary diseases, according to Arineta.
GE HealthCare Debuts AI-Powered Cardiac CT Device at ACC Conference
April 1st 2025Featuring enhanced low-dose image quality with motion-free images, the Revolution Vibe CT system reportedly facilitates improved diagnostic clarity for patients with conditions ranging from in-stent restenosis to atrial fibrillation.
The Reading Room: Racial and Ethnic Minorities, Cancer Screenings, and COVID-19
November 3rd 2020In this podcast episode, Dr. Shalom Kalnicki, from Montefiore and Albert Einstein College of Medicine, discusses the disparities minority patients face with cancer screenings and what can be done to increase access during the pandemic.
Can Photon-Counting CT be an Alternative to MRI for Assessing Liver Fat Fraction?
March 21st 2025Photon-counting CT fat fraction evaluation offered a maximum sensitivity of 81 percent for detecting steatosis and had a 91 percent ICC agreement with MRI proton density fat fraction assessment, according to new prospective research.
